Patent intelligence · US
US 10940142
Inhibition of crystal growth of roflumilast
Inhibition of crystal growth of roflumilast
Patent details — US 10940142
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 9, 2021
- Expiration
- Mar 4, 2041
- Applicant
- Arcutis, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/10
Quick answer
US 10940142 (Inhibition of crystal growth of roflumilast) is held by Arcutis, Inc.. Status: granted. Granted Mar 9, 2021. Expires Mar 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arcutis, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014, A61K9/06
More from Arcutis, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12390453
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 12336983
Inhibition of crystal growth of roflumilast
granted -
US 12329751
Topical roflumilast formulation having antifungal properties
granted -
US 12310956
Topical roflumilast formulation having improved delivery and plasma half-life
granted -
US 12257242
Inhibition of crystal growth of roflumilast
granted -
US 12220409
Roflumilast formulations with an improved pharmacokinetic profile
granted -
US 12161643
Stable formulations of SHR0302
granted -
US 12144802
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
granted
Frequently asked questions
What is US patent 10940142?
US 10940142 (Inhibition of crystal growth of roflumilast) is held by Arcutis, Inc.. Status: granted. Granted Mar 9, 2021. Expires Mar 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10940142?
Arcutis, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 10940142 expire?
Our index shows an expiration date of Mar 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.